Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P49674

UPID:
KC1E_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P49674

BACKGROUND:
The protein Casein kinase I isoform epsilon, with the unique identifier P49674, is operationally defined by its activity on acidic substrates like caseins. It is a central component in the Wnt signaling pathway, phosphorylating DVL1 and DVL2, and plays a crucial role in the circadian rhythm by regulating PER1 and PER2. Its functions extend to inhibiting granulocytic differentiation, showcasing its broad regulatory impact on cell physiology.

THERAPEUTIC SIGNIFICANCE:
The exploration of Casein kinase I isoform epsilon's functions offers a promising avenue for therapeutic intervention. Its critical roles in signaling and circadian regulation present it as an attractive target for the development of novel treatments, potentially addressing a wide range of diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.